EU/3/20/2276: Orphan designation for the treatment of retinal detachment
Table of contents
On 4 June 2020, orphan designation EU/3/20/2276 was granted by the European Commission to Helio Vision Germany GmbH, Germany, for methotrexate for the treatment of retinal detachment.
Treatment of retinal detachment
|Orphan designation status||
|EU designation number||
|Date of designation||
Helio Vision Germany GmbH
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: